About MorphoSys
MorphoSys is a company based in Planegg (Germany) founded in 1992 by Andreas Pluckthun was acquired by Novartis in February 2024. The company has 732 employees as of December 31, 2021. MorphoSys has completed 4 acquisitions, including Biogenesis, Constellation Pharma and Lanthio Pharma. MorphoSys operates in a competitive market with competitors including Merck, AbbVie, Lilly, BeiGene and Roche, among others.
- Headquarter Planegg, Germany
- Employees 732 as on 31 Dec, 2021
- Founders Andreas Pluckthun
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
-$126.36 M (USD)-48as on Dec 31, 2020
-
EBITDA
-$124.85 M (USD)-45as on Dec 31, 2020
-
Latest Funding Round
$383.84 M (USD), Post-IPO
Oct 13, 2020
-
Investors
Novartis
& 1 more
-
Employee Count
732
as on Dec 31, 2021
-
Investments & Acquisitions
Biogenesis
& 3 more
-
Acquired by
Novartis
(Feb 06, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of MorphoSys
Unlock access to complete
Unlock access to complete
Leadership Team
194 people
Software Development Team
81 people
Senior Team
64 people
Sales and Marketing
49 people
Data Analysis and Operations Team
28 people
Human Resources and Administration
22 people
Product Management Team
20 people
Operations Team
19 people
Unlock access to complete
Funding Insights of MorphoSys
Investors in MorphoSys
MorphoSys has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novartis and Incyte.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecules are developed for cancer and skin disease treatments.
|
Locked | Locked | Locked | |
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for MorphoSys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MorphoSys
MorphoSys has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Biogenesis, Constellation Pharma and Lanthio Pharma.
Investment portfolio details for MorphoSys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Speciality company developing and commercializing therapeutic peptide drugs against difficult to target receptors
|
Locked | Locked | 2010 | Locked | |
|
Developer of drugs in the field of epigenetics
|
Locked | Locked | 2008 | Locked | |
|
Technology for the construction of protein libraries
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for MorphoSys
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MorphoSys
Detailed financials for MorphoSys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Morphosys Comparisons
Peer comparison for MorphoSys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MorphoSys
MorphoSys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, BeiGene and Roche, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
Detailed competitors of MorphoSys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Morphosys
Complete news archive for MorphoSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MorphoSys
MorphoSys was founded in 1992 and raised its 1st funding round 21 years after it was founded.
MorphoSys is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Jean-Paul Kress is the current CEO of MorphoSys.
As of Dec 31, 2021, the latest employee count at MorphoSys is 732.
Founded in 1992 and based in Planegg, Germany, MorphoSys operates as an integrated biopharma company focused on the discovery, development, and commercialization of therapeutic antibodies. Targets include cancer, Alzheimers disease, infectious diseases, cardiovascular dysfunction, and inflammation. Key technologies encompass HuCAL and Ylanthia libraries for generating human antibodies. The lead product candidate, MOR208, addresses diffuse large B-cell lymphoma.
MorphoSys's top competitors include Merck, Moderna and Roivant Sciences.
MorphoSys has made 4 acquisitions, including Biogenesis, Constellation Pharma, and Lanthio Pharma.